Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 8Neoplasm Metastasis 3Neoplasms 2Carcinoma, Pancreatic Ductal 2Adenocarcinoma 2Thromboembolism 1Stomach Neoplasms 1Recurrence 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Adenocarcinoma 1Metastatic Pancreatic Adenocarcinoma 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Gemcitabine 112Cisplatin 76Oxaliplatin 44pembrolizumab 34Fluorouracil 32Capecitabine 30durvalumab 27Leucovorin 26lenvatinib 23Magnetic Resonance Spectroscopy 15Irinotecan 14Nivolumab 12Biopsy 12Albumin-Bound Paclitaxel 12tislelizumab 11Specimen Handling 11Radiofrequency Ablation 11Drug Therapy 11pemigatinib 10apatinib 10Taxes 10Floxuridine 10130-nm albumin-bound paclitaxel 10Radiotherapy 9Bevacizumab 9Platinum 8Folfox protocol 8Carboplatin 81,2-diaminocyclohexaneplatinum II citrate 8tremelimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cholangiocarcinoma × PEGPH20 × Clear all
NCT03267940 2020-02-07

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Halozyme Therapeutics

Phase 1 Terminated
85 enrolled 17 charts
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡